New drug pricing analysis reveals where PBMs and pharmacies make their money

For the first time in our existence, CMS has released drug pricing data that overlaps with the date of our launch. As we ripped open the data and examined CMS’ gift, we found some major changes in the way that the state of Ohio reported their data – and it has revealed some eye-opening information about PBM and pharmacy margins on prescription drugs. Given all the drug pricing noise out of Ohio, and the federal heat on PBM “spread pricing,” we decided to do a deep dive into what’s happening in Ohio, and how its new data provides incredible clues to determine where the money flows within the drug supply chain.

Ben LinkApril 21, 2019Ohio, Medicaid, spread pricing, NADAC, PBM, Abilify, Aripiprazole, Ziagen, Abacavir, Nexium, Esomeprazole, Invega, Paliperidone, Crestor, Rosuvastatin, Protopic, Tacrolimus, Plaquenil, hydroxychloroquine, Gleevec, Imatinib, Xeloda, Capecitabine, Viagra, Sildenafil, Revatio, Reyataz, Atazanavir, Valcyte, Valganciclovir, Viread, Tenofovir, CVS, Prilosec, Omeprazole, Suboxone, Buprenorphine-Naloxone

Examining high drug markups: Introducing the Top 20 over $20

We’re told that drug prices are too high, but who actually is setting the price and where does the money end up going? CMS recently updated their State Utilization databases, which track what state Medicaid programs are being charged for prescription drugs. Most notably, they extended the 2018 data to include the second quarter. We have updated our datasets and visualizations to track the changes in drug markups relative to their actual costs. We’ve studied up and have come up with our “Top 20 over $20” list. In other words, the top 20 drugs dispensed through Medicaid managed care organizations (MCOs) with a markup in of over $20 per prescription. Think of it as a “top 40 under 40” list for generic drugs, with the main difference being that no self-respecting generic drug wants to be on this list. Check out our new visualization that highlights the drugs that are busting the budgets of state Medicaid programs.

Ben LinkOctober 30, 2018NADAC, 20 over 20, Medicaid, New York, Markup, Suboxone, PBM, Abilify, Aripiprazole, GoodRx, Gleevec, Imatinib, Specialty, Xeloda, Capecitabine, New Hampshire, Massachusetts, Georgia, Nexium, Esomeprazole, Viread, Tenofovir, Renvela, Sevelamer